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Abstract: Motor neurons typically have very long axons, and fine-tuning axonal transport 
is crucial for their survival. The obstruction of axonal transport is gaining attention as a 
cause of neuronal dysfunction in a variety of neurodegenerative motor neuron diseases. 
Depletions  in  dynein  and  dynactin-1,  motor  molecules  regulating  axonal  trafficking, 
disrupt  axonal  transport  in  flies,  and  mutations  in  their  genes  cause  motor  neuron 
degeneration  in  humans  and  rodents.  Axonal  transport  defects  are  among  the  early 
molecular events leading to neurodegeneration in mouse models of amyotrophic lateral 
sclerosis (ALS). Gene expression profiles indicate that dynactin-1 mRNA is downregulated 
in degenerating spinal motor neurons of autopsied patients with sporadic ALS. Dynactin-1 
mRNA is also reduced in the affected neurons of a mouse model of spinal and bulbar 
muscular atrophy, a motor neuron disease caused by triplet CAG repeat expansion in the 
gene encoding the androgen receptor. Pathogenic androgen receptor proteins also inhibit 
kinesin-1  microtubule-binding  activity  and  disrupt  anterograde  axonal  transport  by 
activating  c-Jun  N-terminal  kinase.  Disruption  of  axonal  transport  also  underlies  the 
pathogenesis  of  spinal  muscular  atrophy  and  hereditary  spastic  paraplegias.  These 
observations  suggest  that  the  impairment  of  axonal  transport  is  a  key  event  in  the 
pathological processes of motor neuron degeneration and an important target of therapy 
development for motor neuron diseases. 
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1. Introduction 
Motor neurons are highly specialized cells that possess the longest axons (more than 1 m long in 
human), which connect the soma with synaptic sites distant from the cell body. Moreover, although 
axons can represent >99% of the volume of a cell, protein and lipid syntheses occur almost exclusively 
in the cell body [1]. Therefore, active transport is required to supply the axon with newly synthesized 
materials and to transport neurotrophic factors and damaged organelles  from the axon terminal to  
the  cell  body  [2–4].  The  major  components  of  axonal  transport  are  a  group  of  specialized  motor 
proteins and the cytoskeletal networks of microtubules and actin filaments. An increasing number of 
reports link defects in axonal transport with motor neuron degenerations, such as amyotrophic lateral 
sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA), spinal muscular atrophy (SMA), and 
hereditary  spastic  paraplegias  (HSPs)  [1,5].  Moreover,  several  studies  identified  mutations  in 
microtubule-based motor proteins of the kinesin and dynein superfamilies in certain hereditary forms 
of motor neuron diseases (MNDs): mutations in the  genes encoding kinesin 1 motors (KIF5A)  in 
certain types of HSPs [6]; two missense mutations in the dynein gene in the Loa and Cra mouse 
models of ALS [7]; and a mutation in the dynactin-1 gene linked to a familial form of lower motor 
neuron disease [8]. Dysfunctions of various membrane-associated proteins also cause motor neuron 
diseases by impairing the efficient transport of cargos such as mitochondria and endosomes. In this 
article, we summarize the current knowledge of the relationships between axonal transport defects and 
the pathogeneses of MNDs. 
2. Motor Proteins and Motor Neuron Disease 
2.1. Dynein/Dynactin Complex  
Cytoplasmic dynein consists of two homodimerized heavy chains and multiple accessory proteins, 
including intermediate, light intermediate, and light chains [9], and is a major motor driving retrograde 
transport in cells. Dynein is involved in a variety of intracellular motile processes, including mitosis, 
maintenance of the Golgi apparatus, and the trafficking of membranous vesicles and other intracellular 
particles [5,10,11]. Two dynein mutant mouse strains, Legs at odd angles (Loa) and Cramping1 (Cra1), 
were identified in a screen for genes involved in late onset MND [7]. Heterozygous mice carrying 
these mutations exhibit an age-related progressive loss of muscle tone and locomotor ability [7]. The 
mechanisms  by  which  these  mutations  cause  neurodegeneration  are  still  discussed.  Although 
Hafezparast et al. demonstrated that the Loa mutation causes axonal transport defect by using an assay 
for the visualization and quantitation of axonal retrograde transport of motor neuron cultures from 
Loa/Loa mouse based on a fluorescent fragment of tetanus toxin (TeNT HC), heterozygous knock out 
of dynein did not exacerbate, but ameliorated, axonal transport in a mutant  superoxide dismutase 1 Int. J. Mol. Sci. 2012, 13                       
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(SOD1) mouse model of ALS [7,12]. Moreover, Ori-McKenney et al. reported that neurodegeneration 
in the Loa
+/− mutant mouse is unlikely to result from dynein subunit dissociation or dissociation of 
dynein from its cargo, but from an altered interaction between dynein and microtubules [13]. On the 
other hand, another mutation of dynein, sprawling (Swl), induces an early-onset sensory neuropathy, 
but not progressive motor neuron loss, in the heterozygous knock out mice for this gene, indicating the 
perplexing  relationship  between  dynein  mutations  and  axonal  transport  [14].  In  addition  to  the 
mutations  in  dynein,  a  G59S  mutation  in  the  P150
Glued subunit  of  dynactin  (dynactin-1)  has  been 
identified in families with a slowly progressive, autosomal dominant form of lower motor neuron 
disease [8]. Dynactin is a multiprotein complex associated with dynein [15] and is required to attach 
dynein to its cargos [16]. Indeed, the dynactin depletion model of Drosophila exhibited disrupted 
axonal  transport  [17].  The  G59S  substitution  occurs  in  the  highly  conserved  CAP-Gly  motif  of 
dynactin-1,  a  domain  that  binds  directly  to  microtubules  [8]  and  slows  transport  of  organelles  
in  vitro  [18].  The  G59S-mutated  protein  also  has  an  enhanced  propensity  to  misfold  and  forms 
aggregates in which trapped organelles, such as mitochondria, are found. Although early degeneration 
of axons and neuromuscular junctions are the common features of three different mouse models of 
mutant G59S [19,20], whether an axonal transport defect is present in these models has yet to be 
elucidated. Lai et al. reported that the retrograde transport of neurofilaments and synaptophysin were 
affected in motor neurons of heterozygous knock-in mice with G59S mutant dynactin-1 [21]. However, 
Chevalier-Larsen et al. demonstrated the absence of axonal transport defects in their transgenic mouse 
model  by  performing  a  double  ligation  assay  on  sciatic  nerves  [19].  To  resolve  this  discrepancy, 
further experiments, such as in vivo imaging of axons, are needed to analyze the transport of cargos, 
and it is also important to generate and analyze dynactin-1 depletion models. 
2.2. Kinesin 
The kinesin superfamily proteins (KIFs) comprise three major groups: N-terminal motor domain 
KIFs (N-KIFs), middle motor domain KIFs (M-KIFs), and C-terminal motor domain KIFs (C-KIFs), 
and  are  mainly  responsible  for  the  anterograde  transport  of  the  various  materials  to  nerve  
terminals [22–24]. KIF5A encodes a neuron-specific, kinesin-1 heavy chain member of the kinesin 
superfamily, which has been implicated in MND. Mutations in the gene for the KIF5A subunit of 
kinesin  1  (formerly  SPG10)  are  associated  with  an  early-onset,  pure  form  of  HSP,  exhibiting  a  
dying-back neuropathy characterized by progressive weakness and spasticity of the legs [5,25]. The 
pathological  mechanism  underlying  this  mutant  is  the  disruption  of  KIF5A’s  ability  to  bind  with 
microtubules,  leading  to  a  failure  of  adequate  anterograde  transport  [26].  Because  KIF5A  motor 
proteins transport many cargos that are important for neurons, including neurofilaments, mitochondria, 
and  SNARE  proteins  essential  for  synaptic  vesicle  docking  [27,28],  disruption  of  KIF5A  motility 
results in dysregulation of axonal homeostasis. In addition to mutations in the kinesin family itself, 
modifications of the motor domain are also potential causes of MNDs [29].  Int. J. Mol. Sci. 2012, 13                       
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3. Axonal Transport Defects and Cargo Accumulation 
As a result of the decreased motility of motor proteins or their decreased binding to motor proteins, 
various cargos of motor proteins are accumulated in degenerated motor neurons. Among these we 
highlight three of the major cargos, neurofilaments, mitochondria, and autophagosomes, accumulations 
of which are the pathological hallmarks of various MNDs.  
3.1. Neurofilaments 
Neurofilaments are made up of three components, neurofilament light chain (NF-L), middle chain 
(NF-M), and heavy chain (NF-H). Neurofilament assembly in the axon is essential for establishing 
proper axon diameter, and its aggregates have long been recognized as a characteristic pathological 
change  in  MNDs  [30–32].  Neurofilaments  are  transported  along  microtubules  by  kinesin  and  the 
dynein/dynactin-1  complex,  and  dysfunctions  of  these  motor  proteins  lead  to  accumulation  of 
neurofilaments in axons and somata, as observed in the KIF5A mutant mouse and dynactin-1 mutant 
mouse [20,30,33,34]. Moreover, mutations in neurofilaments also cause motor neuron degeneration. 
Mersiyanova  et  al.  reports  that  the  A998C  transversion  in  the  first  exon  of  NF-L  results  in  
Charcot-Marie-Tooth (CMT) type 2 [35]. The missense mutations in NF-L observed in CMT lead to 
disruption of axonal transport of neurofilaments and to the subsequent assembly and aggregation of 
NF-L in neuronal cells and in primary cultured neurons [36,37]. These studies strongly suggest that 
disruption of the axonal transport of neurofilaments is one of the underlying pathogenic mechanisms in 
the development of MNDs. 
3.2. Mitochondria 
Growing evidence suggests that mitochondrial damage is involved in motor neuron degeneration in 
CMT, HSP, and ALS. Local energy synthesis by mitochondria is essential to axonal homeostasis and 
its  altered  distribution  and  dysfunction  play  critical  roles  in  axonal  degeneration.  Because 
mitochondria  are  transported  by  kinesin  and  the  dynein/dynactin  complex  [24],  defects  in  axonal 
transport  result  in  abnormal  accumulation  of  mitochondria.  It  has  been  shown  that  mitochondria 
accumulate  in  the  axons  of  spinal  motor  neurons  in  mouse  mutant  SOD1  models  [38–40]  and  in 
sporadic ALS (SALS) patients [41], suggesting an impairment of axonal transport in ALS. Indeed, in 
mutant SOD1 models, a defect in the axonal transport of mitochondria in sciatic nerves was directly 
observed  during  the  presymptomatic  stage  [39].  Moreover,  the  presence  of  mitochondria  with 
abnormal morphology, observed in both ALS models and SALS patients, indicates a poor recycling or 
degradation of abnormal mitochondria due to impaired retrograde transport [42–44].  
It is important to assess whether the activation of mitochondrial mobility in axons has a beneficial 
effect on axonal degeneration in MNDs. It is proposed that increased mitochondrial transport might aid 
the efficient delivery of healthy mitochondria to axons and/or the removal of damaged mitochondria 
from the periphery. However, Zhu et al. reported that mutant SOD1 mice crossed with syntaphilin 
knock-out  mice  that  have  a  higher  proportion  of  axonal  mitochondrial  mobility,  displayed  no 
observable improvement in the deterioration of motor function or in disease progression and lifespan [45]. 
They suggested that mitochondrial dysfunction, rather than impaired mobility, may be more important Int. J. Mol. Sci. 2012, 13                       
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for mutant SOD1 toxicity. On the other hand, a mouse model of mutant HSPB1-induced CMT exhibits 
impaired axonal transport of mitochondria, and treatment with histone deacetylase 6 inhibitors restored 
mitochondrial transport and attenuated the motor phenotype of this model [46]. 
3.3. Autophagosomes 
The autophagy-lysosome pathway is responsible for the highly regulated recycling of intracellular 
contents, and it is well known that dysfunction of this pathway causes neurodegeneration [47,48]. 
Abnormal intraneuronal accumulation of autophagosomes is observed in various neurodegenerative 
diseases, including Alzheimer’s disease [49], Parkinson’s disease [50], and Huntington’s disease [51]. 
Because the autophagosome is a cargo that moves bidirectionally along microtubules powered by the 
kinesin  family  of  motor  proteins  and  the  dynein/dynactin  complex  [52–55],  the  autophagosomes 
accumulates  in  those  motor  neurons  with  altered  axonal  transport.  Human  pathology  and  animal 
models  of  motor  neuron  disease  also  exhibited  the  same  accumulations  of  autophagosomes,  for 
example  in  SALS  patients  [56],  the  mutant  dynein  model  (Loa  mouse)  [47],  and  in  the  mutant 
dynactin-1  mouse  model  [20].  Abnormal  organelles,  such  as  damaged  mitochondria  and  dilated 
endoplasmic reticulum, are also observed in these motor neurons, and organelle accumulations are also 
observed in the neuritis of the Atg7
−/− mouse, which cannot form autophagosomes [48]. Therefore, 
disruption of autophagosomal transport resulting in the dysfunction of the autophagy system in axons 
is construed to be a causative mechanism of axonal degeneration. 
4. MND and Axonal Transport Defects 
MNDs affect various motor systems, including corticospinal upper motor neurons, lower motor 
neurons, neuromuscular junctions, and skeletal muscles. Impairments of these systems result in various 
motor phenotypes, such as muscle atrophy, weakness, and spasticity. Recent studies implicate axonal 
transport defects in the pathogeneses of MNDs (Table 1). 
Table 1. Gene mutations in motor neuron diseases (MNDs) affecting axonal transport. 
MND 
type       
Gene 
symbol       
Protein        Protein function        Phenotype        Ref. 
ALS1  SOD1 
Cu/Zn superoxide 
dismutase 
Detoxification enzyme 
Varies among 
mutations from 
typical ALS type to 
atypical ALS 
[57] 
ALS2  ALS2  Alsin 
Guanine nucleotide 
exchange factor (GEF) 
signaling; controlling 
endosomal dynamics 
Juvenile onset, 
progressive muscle 
weakness and 
paralysis 
[58] 
ALS8 
and 
SMA 
VAPB 
Synaptobrevin-
associated 
membrane  
protein B (VAPB) 
Vesicular trafficking; 
acts during ER-Golgi 
transport and secretion 
Adult onset, slowly 
progressive upper and 
lower motor neuron 
disease. Phenotype 
varies from SMA type 
to ALS type 
[59] Int. J. Mol. Sci. 2012, 13                       
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Table 1. Cont. 
MND type       
Gene 
symbol       
Protein        Protein function        Phenotype        Ref. 
Lower 
motor 
neuron 
disease 
DCTN1 
Dynactin-1 
(p150
glued) 
Retrograde axonal 
transport 
Slowly progressive 
lower motor neuron 
disease 
[8,18] 
ALS  CHMP2B 
Charged 
multivesicular 
body protein 
2B (CHMP2B) 
Vesicular trafficking; acts 
as a component of the 
ESCRTIII (endosomal 
secretory complex 
required for transport) 
complex 
Lower dominant 
motor neuron disease 
[60,61] 
SBMA  AR 
Androgen 
receptor 
DNA-binding 
transcription factor 
Slowly progressive 
lower motor neuron 
disease 
[29,62,63] 
SPG3  ATL1  Atlastin 
Vesicular trafficking; a 
member of GTPase 
family, essential for axon 
formation and elongation 
Early-onset pure, 
slow progression 
HSP 
[64,65] 
SPG4  SPAST  Spastin 
An ATPase belonging to 
the AAA family acting 
for microtubule dynamics 
Mainly pure HSP 
with variable onset 
[66] 
SPG10  Kif5A 
Kinesin 
(K1F5A) 
Anterograde axonal 
transport 
Early onset 
progressive weakness 
and leg spasticity 
[33] 
ALS.  Amyotrophic  lateral  sclerosis  is  a  fatal  neurodegenerative  disease  characterized  by 
progressive loss of motor neurons [67]. Approximately 10% of ALS cases are familial (FALS) with 
inheritance patterns, while 90% are sporadic (SALS) with no known genetic defect [68,69]. There is at 
present no obvious consensus understanding of the pathogenic mechanism of SALS; however, the 
abnormal  accumulation  of  neurofilaments,  damaged  mitochondria,  and  autophagosomes  present  in 
motor  neurons  of  SALS  patients  [41,44,56,70],  suggests  that  axonal  transport  defects  might  be 
implicated in the pathogenesis, but the molecular mechanisms causing axonal transport defects are  
still unclear.  
To uncover this mechanism, we created a motor neuron-specific gene expression profile in patients 
with SALS using microarray technology combined with laser-captured microdissection, the results  
of  which  were  further  verified  by  in  situ  hybridization  and  quantitative  wide-ranging  research  
activities [71]. Among the genes with dysregulated expressions, dynactin-1 was markedly and widely 
downregulated  in  SALS  motor  neurons  [71].  Furthermore,  we  found  that  the  downregulation  of 
dynactin-1  occurs  prior  to  the  accumulation  of  phosphorylated-neurofilament,  which  is,  again,  a 
marker of defective axonal transport and is considered a rather early marker of neurodegeneration 
(Figure 1) [72]. The dramatic change in dynactin-1 in patients with SALS seems to be specific for 
motor neurons, as dynactin-1 expression was preserved in neurons in the dorsal nucleus of Clarke and Int. J. Mol. Sci. 2012, 13                       
 
 
1231 
the intermediolateral nucleus in the spinal cord, Purkinje cells of the cerebellum, and cortical neurons 
in the occipital cortex. By taking into account that mutations in dynactin-1 cause MNDs, these results 
strongly suggest that the downregulation of dynactin-1 in motor neurons may play a significant role in 
motor neuron degeneration in SALS.  
Figure 1. Dysregulation of dynactin-1 in amyotrophic lateral sclerosis (ALS). (a) In situ 
hybridization of antisense (AS) and sense (S) dynactin-1 probes in spinal motor neurons of 
control and ALS subjects; (b) Relationship between the number of residual motor neurons 
and the percentage of neurons with decreased dynactin-1 (Reproduced from Jiang et al. [72]). 
 
SBMA.  Spinal  and  bulbar  muscular  atrophy,  or  Kennedy’s  disease,  is  a  hereditary 
neurodegenerative disease characterized by a loss of bulbar and spinal motor neurons [63,73]. The 
causative molecular defect in SBMA is the expansion of a trinucleotide CAG repeat, which encodes a 
polyglutamine tract in the first exon of the AR gene [74]. The resulting mutant AR forms aggregations 
in  the  nucleus  and  affects  the  expression  of  various  genes  by  inhibiting  transcription  factors  and 
coactivators [75,76]. Polyglutamine-expanded AR inhibits axonal transport via a pathway involving 
cJun N-terminal kinase (JNK) activation, phosphorylation of kinesin-1 heavy chain subunits by JNK, 
and inhibition of kinesin-1 function [29]. Interestingly, we found that dynactin-1 is downregulated in 
the spinal motor neurons of SBMA patients and transgenic model mice (Figure 2) [62], which is also 
observed in SALS patients [71,72]. Fluoro-gold labeling revealed that retrograde axonal transport in 
SBMA mice was significantly impaired. Moreover, abnormal accumulations of neurofilaments and 
synaptic proteins were observed in the distal part of axons in these mice. The retrograde transport 
defects  preceded  the  onset  of  motor  symptoms,  and  were  restored  by  hormonal  interventions  that 
prevent accumulations of mutant AR in the nucleus. The disruption of retrograde axonal transport was 
also documented in a knock-in mouse model of SBMA and in mice over-expressing wildtype AR in 
muscle [77], although this was not the case in another mouse model of SBMA [78]. Int. J. Mol. Sci. 2012, 13                       
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Figure 2. Disrupted retrograde axonal transport in a mouse model of spinal and bulbar 
muscular  atrophy  (SBMA).  (a)  Immunofluorescent  anti-α-bungarotoxin  (green)  and  
anti-phospho  NF-H  (red)  antibody  staining  of  mouse  skeletal  muscle.  Phosphorylated  
NF-H  accumulates  in  the  distal  end  of  motor  axons  in  the  SBMA  mice  (AR-97Q);  
(b)  Retrograde  labeling  of  lumbar  motor  neurons  by  Fluoro-gold  injection  into  the 
gastrocnemius  muscle  demonstrated  decreased  retrograde  axonal  transport  in  AR-97Q 
mice;  (c)  Immunohistochemistry  shows  decreased  expression  of  dynactin-1  in  motor 
neurons  of  spinal  cord  and  brainstem  of  AR-97Q  mice  compared  with  wildtype  mice. 
Accumulation  of  pathogenic  AR  is  detected  by  1C2,  an  anti-polyglutamine  antibody 
(Reproduced from Katsuno et al. [62]). 
 
SMA.  Spinal  muscular  atrophy  is  an  autosomal  recessive  disease  that  selectively  affects  lower 
motor neurons and is classified into 3 forms: a severe form (type I; Werdnig–Hoffmann disease), an 
intermediate form (type II), and a juvenile form (type III; Kugelberg–Welander disease). SMA occurs 
in 1/6000 live births and is the leading genetic cause of infantile mortality in the USA. SMA is caused 
by the mutation or deletion of the “survival motor neuron 1” gene (SMN1), which plays an important 
role in RNA metabolism [79]. Reduced levels of SMN1 lead to pathological changes at neuromuscular 
junctions,  including  decreased  synaptic  vesicle  density,  synaptic  transmission  defects,  and 
neurofilament  accumulation [80]. In a mouse model of SMA, fast anterograde  axonal transport is 
disrupted, providing the molecular basis for the synaptic pathology [81]. The levels of dynein in the 
sciatic  nerve  are  also  reduced  in  this  mouse  model,  suggesting  the  concomitant  involvement  of 
retrograde axonal transport [81]. 
HSP.  The  hereditary  spastic  paraplegias  are  a  heterogeneous  group  of  genetic  disorders 
characterized by lower extremity spastic weakness due to retrograde degeneration of the corticospinal 
tracts and posterior columns, which is often accompanied by brisk reflexes, extensor plantar reflexes, 
and urinary urgency [82]. This disorder is classified into pure (uncomplicated) HSP and complicated 
HSP,  depending  on  the  presence  of  other  neurological  features  in  addition  to  spastic  paraparesis. 
Spastic weakness is confined to the lower extremities in pure HSP, whereas complicated HSP is associated 
with  mental  retardation,  ataxia,  extrapyramidal  signs,  visual  dysfunction  or  epilepsy.  Among  the Int. J. Mol. Sci. 2012, 13                       
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causative proteins of HSPs, atlastin, spastin, and K1F5A regulate axonal transport [33,64–66]. While 
atlastin  and  spastin  facilitate  vesicle  trafficking,  KIF5A  regulates  anterograde  axonal  transport  as 
described above. 
5. Conclusions 
The fine-tuning of axonal transport is crucial for the survival of motor neurons, while defects in 
axonal  transport  have  been  implicated  in  the  pathogenesis  of  various  disorders  that  affect  motor 
systems. The elucidation of relationships between axonal transport and motor neuron degeneration is 
key to the development of molecular-targeted therapies and biomarkers for MNDs. 
Acknowledgments 
This work was supported by a Center-of-Excellence (COE) grant, a Grant-in-Aid for Scientific 
Research on Innovated Areas “Foundation of Synapse and Neurocircuit Pathology” [No, 22110005], 
and  Grant-in-Aids  from  the  Ministry  of  Education,  Culture,  Sports,  Science,  and  Technology  of  
Japan [No. 21229011, 22390175]; grants from the Ministry of Health, Labor and Welfare of Japan; 
and  Core  Research  for  Evolutional  Science  and  Technology  (CREST)  of  the  Japan  Science  and 
Technology Agency (JST). 
References 
1.  Holzbaur, E.L. Motor neurons rely on motor proteins. Trends Cell Biol. 2004, 14, 233–240. 
2.  Chao, M.V. Retrograde transport redux. Neuron 2003, 39, 1–2. 
3.  Hollenbeck,  P.J.;  Saxton,  W.M.  The  axonal  transport  of  mitochondria.  J.  Cell  Sci.  2005,  
118, 5411–5419. 
4.  Hollenbeck, P.J. The pattern and mechanism of mitochondrial transport in axons. Front Biosci. 
1996, 1, d91–d102. 
5.  El-Kadi, A.M.; Soura, V.; Hafezparast, M. Defective axonal transport in motor neuron disease. J. 
Neurosci. Res. 2007, 85, 2557–2566. 
6.  Fichera,  M.;  Lo  Giudice,  M.;  Falco,  M.;  Sturnio,  M.;  Amata,  S.;  Calabrese,  O.;  Bigoni,  S.; 
Calzolari, E.; Neri, M. Evidence of kinesin heavy chain (kif5a) involvement in pure hereditary 
spastic paraplegia. Neurology 2004, 63, 1108–1110. 
7.  Hafezparast,  M.;  Klocke,  R.;  Ruhrberg,  C.;  Marquardt,  A.;  Ahmad-Annuar,  A.;  Bowen,  S.;  
Lalli, G.; Witherden, A.S.; Hummerich, H.; Nicholson, S.; et al. Mutations in dynein link motor 
neuron degeneration to defects in retrograde transport. Science 2003, 300, 808–812. 
8.  Puls, I.; Jonnakuty, C.; LaMonte, B.H.; Holzbaur, E.L.; Tokito, M.; Mann, E.; Floeter, M.K.; 
Bidus, K.; Drayna, D.; Oh, S.J.; et al. Mutant dynactin in motor neuron disease. Nat. Genet. 2003, 
33, 455–456. 
9.  Pfister, K.K.; Fisher, E.M.; Gibbons, I.R.; Hays, T.S.; Holzbaur, E.L.; McIntosh, J.R.; Porter, M.E.; 
Schroer, T.A.; Vaughan, K.T.; Witman, G.B.; et al. Cytoplasmic dynein nomenclature. J. Cell 
Biol. 2005, 171, 411–413. 
10.  King, S.M. The dynein microtubule motor. Biochim. Biophys. Acta 2000, 1496, 60–75. Int. J. Mol. Sci. 2012, 13                       
 
 
1234 
11.  Holzbaur, E.L.; Vallee, R.B. Dyneins: Molecular structure and cellular function. Annu. Rev. Cell 
Biol. 1994, 10, 339–372. 
12.  Kieran,  D.;  Hafezparast,  M.;  Bohnert,  S.;  Dick,  J.R.;  Martin,  J.;  Schiavo,  G.;  Fisher,  E.M.; 
Greensmith, L. A mutation in dynein rescues axonal transport defects and extends the life span of 
ALS mice. J. Cell Biol. 2005, 169, 561–567. 
13.  Ori-McKenney,  K.M.;  Xu,  J.;  Gross,  S.P.;  Vallee,  R.B.  A  cytoplasmic  dynein  tail  mutation 
impairs motor processivity. Nat. Cell Biol. 2010, 12, 1228–1234. 
14.  Chen,  X.J.;  Levedakou,  E.N.;  Millen,  K.J.;  Wollmann,  R.L.;  Soliven,  B.;  Popko,  B. 
Proprioceptive  sensory  neuropathy  in  mice  with  a  mutation  in  the  cytoplasmic  Dynein  heavy 
chain 1 gene. J. Neurosci. 2007, 27, 14515–14124. 
15.  Gill, S.R.; Schroer, T.A.; Szilak, I.; Steuer, E.R.; Sheetz, M.P.; Cleveland, D.W. Dynactin, a 
conserved,  ubiquitously  expressed  component  of  an  activator  of  vesicle  motility  mediated  by 
cytoplasmic dynein. J. Cell Biol. 1991, 115, 1639–1650.  
16.  Karki,  S.;  Holzbaur,  E.L.  Affinity  chromatography  demonstrates  a  direct  binding  between 
cytoplasmic dynein and the dynactin complex. J. Biol. Chem. 1995, 270, 28806–28811. 
17.  Haghnia, M.; Cavalli, V.; Shah, S.B.; Schimmelpfeng, K.; Brusch, R.; Yang, G.; Herrera, C.; 
Pilling, A.; Goldstein, L.S. Dynactin is required for coordinated bidirectional motility, but not for 
dynein membrane attachment. Mol. Biol. Cell 2007, 18, 2081–2089.  
18.  Levy, J.R.; Sumner, C.J.; Caviston, J.P.; Tokito, M.K.; Ranganathan, S.; Ligon, L.A.; Wallace, K.E.; 
LaMonte,  B.H.;  Harmison,  G.G.;  Puls,  I.;  et  al.  A  motor  neuron  disease-associated  mutation  
in  p150glued  perturbs  dynactin  function  and  induces  protein  aggregation.  J.  Cell  Biol.  2006,  
172, 733–745. 
19.  Chevalier-Larsen, E.S.; Wallace, K.E.; Pennise, C.R.; Holzbaur, E.L. Lysosomal proliferation and 
distal degeneration in motor neurons expressing the g59s mutation in the p150glued subunit of 
dynactin. Hum. Mol. Genet. 2008, 17, 1946–1955. 
20. Laird, F.M.; Farah, M.H.; Ackerley, S.; Hoke, A.; Maragakis, N.; Rothstein, J.D.; Griffin, J.; Price, 
D.L.; Martin, L.J.; Wong, P.C. Motor neuron disease occurring in a mutant dynactin mouse model 
is characterized by defects in vesicular trafficking. J. Neurosci. 2008, 28, 1997–2005. 
21.  Lai, C.; Lin, X.; Chandran, J.; Shim, H.; Yang, W.J.; Cai, H. The g59s mutation in p150 (glued) 
causes dysfunction of dynactin in mice. J. Neurosci. 2007, 27, 13982–13990. 
22.  Miki, H.; Setou, M.; Kaneshiro, K.; Hirokawa, N. All kinesin superfamily protein, kif, genes in 
mouse and human. Proc. Natl. Acad. Sci. USA 2001, 98, 7004–7011. 
23.  Hirokawa,  N.;  Takemura,  R.  Molecular  motors  and  mechanisms  of  directional  transport  in 
neurons. Nat. Rev. Neurosci. 2005, 6, 201–214. 
24.  Hirokawa, N.; Niwa, S.; Tanaka, Y. Molecular motors in neurons: Transport mechanisms and 
roles in brain function, development, and disease. Neuron 2010, 68, 610–638. 
25.  Reid,  E.;  Kloos,  M.;  Ashley-Koch,  A.;  Hughes,  L.;  Bevan,  S.;  Svenson,  I.K.;  Graham,  F.L.; 
Gaskell, P.C.; Dearlove, A.; Pericak-Vance, M.A.; et al. A kinesin heavy chain (kif5a) mutation in 
hereditary spastic paraplegia (spg10). Am. J. Hum. Genet. 2002, 71, 1189–1194. 
26.  Song,  H.;  Endow,  S.A.  Decoupling  of  nucleotide-  and  microtubule-binding  sites  in  a  kinesin 
mutant. Nature 1998, 396, 587–590. Int. J. Mol. Sci. 2012, 13                       
 
 
1235 
27.  Hirokawa, N.; Noda, Y. Intracellular transport and kinesin superfamily proteins, kifs: Structure, 
function, and dynamics. Physiol. Rev. 2008, 88, 1089–1118. 
28.  Shi,  P.;  Strom,  A.L.;  Gal,  J.;  Zhu,  H.  Effects  of  als-related  SOD1  mutants  on  dynein-  and  
kif5-mediated  retrograde  and  anterograde  axonal  transport.  Biochim.  Biophys.  Acta  2010,  
1802, 707–716. 
29.  Morfini, G.; Pigino, G.; Szebenyi, G.; You, Y.; Pollema, S.; Brady, S.T. Jnk mediates pathogenic 
effects  of  polyglutamine-expanded  androgen  receptor  on  fast  axonal  transport.  Nat.  Neurosci. 
2006, 9, 907–916. 
30.  Lee,  M.K.;  Cleveland,  D.W.  Neuronal  intermediate  filaments.  Annu.  Rev.  Neurosci.  1996,  
19, 187–217. 
31.  Garcia,  M.L.;  Lobsiger,  C.S.;  Shah,  S.B.;  Deerinck,  T.J.;  Crum,  J.;  Young,  D.;  Ward,  C.M.; 
Crawford,  T.O.;  Gotow,  T.;  Uchiyama,  Y.;  et  al.  Nf-m  is  an  essential  target  for  the  
myelin-directed “Outside-in” Signaling cascade that mediates radial axonal growth. J. Cell Biol. 
2003, 163, 1011–1020. 
32.  Bruijn, L.I.; Miller, T.M.; Cleveland, D.W. Unraveling the mechanisms involved in motor neuron 
degeneration in als. Annu. Rev. Neurosci. 2004, 27, 723–749. 
33.  Xia, C.H.; Roberts, E.A.; Her, L.S.; Liu, X.; Williams, D.S.; Cleveland, D.W.; Goldstein, L.S. 
Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain 
kif5a. J. Cell Biol. 2003, 161, 55–66. 
34.  Koehnle, T.J.; Brown, A. Slow axonal transport of neurofilament protein in cultured neurons. J. 
Cell Biol. 1999, 144, 447–458. 
35.  Mersiyanova, I.V.; Perepelov, A.V.; Polyakov, A.V.; Sitnikov, V.F.; Dadali, E.L.; Oparin, R.B.; 
Petrin, A.N.; Evgrafov, O.V. A new variant of charcot-marie-tooth disease type 2 is probably the 
result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet. 2000, 67, 37–46. 
36.  Perez-Olle,  R.;  Jones,  S.T.;  Liem,  R.K.  Phenotypic  analysis  of  neurofilament  light  gene  
mutations linked to charcot-marie-tooth disease in cell culture models. Hum. Mol. Genet. 2004,  
13, 2207–2220. 
37.  Perez-Olle, R.; Lopez-Toledano, M.A.; Goryunov, D.; Cabrera-Poch, N.; Stefanis, L.; Brown, K.; 
Liem, R.K. Mutations in the neurofilament light gene linked to charcot-marie-tooth disease cause 
defects in transport. J. Neurochem. 2005, 93, 861–874. 
38.  Magrane,  J.;  Manfredi,  G.  Mitochondrial  function,  morphology,  and  axonal  transport  in 
amyotrophic lateral sclerosis. Antioxid. Redox. Signal 2009, 11, 1615–1626. 
39.  Bilsland, L.G.; Sahai, E.; Kelly, G.; Golding, M.; Greensmith, L.; Schiavo, G. Deficits in axonal 
transport precede als symptoms in vivo. Proc. Natl. Acad. Sci. USA 2010, 107, 20523–20528. 
40.  Collard, J.F.; Cote, F.; Julien, J.P. Defective axonal transport in a transgenic mouse model of 
amyotrophic lateral sclerosis. Nature 1995, 375, 61–64. 
41.  Sasaki, S.; Iwata, M. Impairment of fast axonal transport in the proximal axons of anterior horn 
neurons in amyotrophic lateral sclerosis. Neurology 1996, 47, 535–540. 
42.  Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.; Sisodia, S.S.; 
Cleveland, D.W.; Price, D.L. An adverse property of a familial als-linked SOD1 mutation causes 
motor  neuron  disease  characterized  by  vacuolar  degeneration  of  mitochondria.  Neuron  1995,  
14, 1105–1116. Int. J. Mol. Sci. 2012, 13                       
 
 
1236 
43.  Kong,  J.;  Xu,  Z.  Massive  mitochondrial  degeneration  in  motor  neurons  triggers  the  onset  
of  amyotrophic  lateral  sclerosis  in  mice  expressing  a  mutant  SOD1.  J.  Neurosci.  1998,  
18, 3241–3250. 
44.  Sasaki,  S.;  Iwata,  M.  Mitochondrial  alterations  in  the  spinal  cord  of  patients  with  sporadic 
amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007, 66, 10–16. 
45.  Zhu, Y.B.; Sheng, Z.H. Increased axonal mitochondrial mobility does not slow als-like disease in 
mutant SOD1 mice. J. Biol. Chem. 2011, 26, 23432–23440. 
46.  d’Ydewalle,  C.;  Krishnan,  J.;  Chiheb,  D.M.;  Van  Damme,  P.;  Irobi,  J.;  Kozikowski,  A.P.;  
Berghe, P.V.; Timmerman, V.; Robberecht, W.; Van Den Bosch,  L. Hdac6 inhibitors reverse 
axonal loss in a mouse model of mutant hspb1-induced charcot-marie-tooth disease. Nat. Med. 
2011, 17, 968–974. 
47.  Ravikumar,  B.;  Acevedo-Arozena,  A.;  Imarisio,  S.;  Berger,  Z.;  Vacher,  C.;  O’Kane,  C.J.;  
Brown, S.D.; Rubinsztein, D.C. Dynein mutations impair autophagic clearance of aggregate-prone 
proteins. Nat. Genet. 2005, 37, 771–776. 
48.  Komatsu,  M.;  Wang,  Q.J.;  Holstein,  G.R.;  Friedrich,  V.L.,  Jr.;  Iwata,  J.;  Kominami,  E.;  
Chait, B.T.; Tanaka, K.; Yue, Z. Essential role for autophagy protein atg7 in the maintenance of 
axonal homeostasis and the prevention of axonal degeneration. Proc. Natl. Acad. Sci. USA 2007, 
104, 14489–14494. 
49.  Yu, W.H.; Cuervo, A.M.; Kumar, A.; Peterhoff, C.M.; Schmidt, S.D.; Lee, J.H.; Mohan, P.S.; 
Mercken,  M.;  Farmery,  M.R.;  Tjernberg,  L.O.;  et  al.  Macroautophagy—a  novel  beta-amyloid 
peptide-generating pathway activated in Alzheimer’s disease. J. Cell Biol. 2005, 171, 87–98. 
50.  Jellinger, K.A. Basic mechanisms of neurodegeneration: a critical update. J. Cell Mol. Med. 2010, 
14, 457–487. 
51.  Sapp, E.; Schwarz, C.; Chase, K.; Bhide, P.G.; Young, A.B.; Penney, J.; Vonsattel, J.P.; Aronin, N.; 
DiFiglia, M. Huntingtin localization in brains of normal and huntington’s disease patients. Ann. 
Neurol. 1997, 42, 604–612. 
52.  Kimura, S.; Noda, T.; Yoshimori, T. Dynein-dependent movement of autophagosomes mediates 
efficient encounters with lysosomes. Cell Struct. Funct. 2008, 33, 109–122. 
53.  Yang, Y.; Xu, K.; Koike, T.; Zheng, X. Transport of autophagosomes in neurites of pc12 cells 
during serum deprivation. Autophagy 2008, 4, 243–245. 
54.  Yue,  Z.;  Wang,  Q.J.;  Komatsu,  M.  Neuronal  autophagy:  Going  the  distance  to  the  axon. 
Autophagy 2008, 4, 94–96. 
55.  Katsumata, K.; Nishiyama, J.; Inoue, T.; Mizushima, N.; Takeda, J.; Yuzaki, M. Dynein- and 
activity-dependent retrograde transport of autophagosomes in neuronal axons. Autophagy 2010,  
6, 378–385. 
56.  Sasaki, S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J. 
Neuropathol. Exp. Neurol. 2011, 70, 349–359. 
57.  Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; 
Goto, J.; O’Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are 
associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59–62. 
58.  Otomo, A.; Hadano, S.; Okada, T.; Mizumura, H.; Kunita, R.; Nishijima, H.; Showguchi-Miyata, J.; 
Yanagisawa, Y.; Kohiki, E.; Suga, E.; et al. Als2, a novel guanine nucleotide exchange factor  Int. J. Mol. Sci. 2012, 13                       
 
 
1237 
for  the  small  gtpase  rab5,  is  implicated  in  endosomal  dynamics.  Hum.  Mol.  Genet.  2003,  
12, 1671–1687. 
59.  Nishimura,  A.L.;  Mitne-Neto,  M.;  Silva,  H.C.;  Richieri-Costa,  A.;  Middleton,  S.;  Cascio,  D.;  
Kok, F.; Oliveira, J.R.; Gillingwater, T.; Webb, J.; et al. A mutation in the vesicle-trafficking 
protein vapb causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. 
Hum. Genet. 2004, 75, 822–831. 
60.  Parkinson, N.; Ince, P.G.; Smith, M.O.; Highley, R.; Skibinski, G.; Andersen, P.M.; Morrison, K.E.; 
Pall, H.S.; Hardiman, O.; Collinge, J.; et al. Als phenotypes with mutations in chmp2b (charged 
multivesicular body protein 2b). Neurology 2006, 67, 1074–1077. 
61.  Cox,  L.E.;  Ferraiuolo,  L.;  Goodall,  E.F.;  Heath,  P.R.;  Higginbottom,  A.;  Mortiboys,  H.;  
Hollinger,  H.C.;  Hartley,  J.A.;  Brockington,  A.;  Burness,  C.E.;  et  al.  Mutations  in  chmp2b  
in  lower  motor  neuron  predominant  amyotrophic  lateral  sclerosis  (als).  PLoS  One  2010,  5, 
doi:10.1371/journal.pone.0009872. 
62.  Katsuno,  M.;  Adachi,  H.;  Minamiyama,  M.;  Waza,  M.;  Tokui,  K.;  Banno,  H.;  Suzuki,  K.;  
Onoda,  Y.;  Tanaka,  F.;  Doyu,  M.;  et  al.  Reversible  disruption  of  dynactin-1-mediated  
retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci. 
2006, 26, 12106–12117. 
63.  Sobue,  G.;  Hashizume,  Y.;  Mukai,  E.;  Hirayama,  M.;  Mitsuma,  T.;  Takahashi,  A.  X-linked 
recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989, 112, 209–232. 
64.  Zhao, X.; Alvarado, D.; Rainier, S.; Lemons, R.; Hedera, P.; Weber, C.H.; Tukel, T.; Apak, M.; 
Heiman-Patterson,  T.;  Ming,  L.;  et  al.  Mutations  in  a  newly  identified  gtpase  gene  cause 
autosomal dominant hereditary spastic paraplegia. Nat. Genet. 2001, 29, 326–331. 
65.  Rismanchi,  N.;  Soderblom,  C.;  Stadler,  J.;  Zhu,  P.P.;  Blackstone,  C.  Atlastin  GTPases  are 
required for Golgi apparatus and ER morphogenesis. Hum. Mol. Genet. 2008, 17, 1591–1604. 
66.  Hazan,  J.;  Fonknechten,  N.;  Mavel,  D.;  Paternotte,  C.;  Samson,  D.;  Artiguenave,  F.;  
Davoine, C.S.; Cruaud, C.; Durr, A.; Wincker, P.; et al. Spastin, a new aaa protein, is altered in 
the most frequent form of autosomal dominant spastic paraplegia. Nat. Genet. 1999, 23, 296–303. 
67.  Rowland,  L.P.;  Shneider,  N.A.  Amyotrophic  lateral  sclerosis.  N.  Engl.  J.  Med.  2001,  
344, 1688–1700. 
68.  Ince,  P.G.;  Highley,  J.R.;  Kirby,  J.;  Wharton,  S.B.;  Takahashi,  H.;  Strong,  M.J.;  Shaw,  P.J. 
Molecular  pathology  and  genetic  advances  in  amyotrophic  lateral  sclerosis:  an  emerging 
molecular  pathway  and  the  significance  of  glial  pathology.  Acta  Neuropathol.  2011,  
122, 657–671. 
69.  Wroe,  R.;  Wai-Ling  Butler,  A.;  Andersen,  P.M.;  Powell,  J.F.;  Al-Chalabi,  A.  ALSOD:  the 
Amyotrophic Lateral Sclerosis Online Database. Amyotroph. Lateral. Scler. 2008, 9, 249–250. 
70.  Sasaki, S.; Warita, H.; Abe, K.; Iwata, M. Impairment of axonal transport in the axon hillock and 
the initial segment of anterior horn neurons in transgenic mice with a G93A mutant SOD1 gene. 
Acta Neuropathol. 2005, 110, 48–56. 
71.  Jiang, Y.M.; Yamamoto, M.; Kobayashi, Y.; Yoshihara, T.; Liang, Y.; Terao, S.; Takeuchi, H.; 
Ishigaki, S.; Katsuno, M.; Adachi, H.; et al. Gene expression profile of spinal motor neurons in 
sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005, 57, 236–251. Int. J. Mol. Sci. 2012, 13                       
 
 
1238 
72.  Jiang,  Y.M.;  Yamamoto,  M.;  Tanaka,  F.;  Ishigaki,  S.;  Katsuno,  M.;  Adachi,  H.;  Niwa,  J.;  
Doyu, M.; Yoshida, M.; Hashizume, Y.; et al. Gene expressions specifically detected in motor 
neurons (dynactin-1, early growth response 3, acetyl-coa transporter, death receptor 5, and cyclin 
c)  differentially  correlate  to  pathologic  markers  in  sporadic  amyotrophic  lateral  sclerosis.  J. 
Neuropathol. Exp. Neurol. 2007, 66, 617–627. 
73.  Kennedy, W.R.; Alter, M.; Sung, J.H. Progressive proximal spinal and bulbar muscular atrophy of 
late onset. A sex-linked recessive trait. Neurology 1968, 18, 671–680. 
74.  La Spada, A.R.; Wilson, E.M.; Lubahn, D.B.; Harding, A.E.; Fischbeck, K.H. Androgen receptor 
gene mutations in x-linked spinal and bulbar muscular atrophy. Nature 1991, 352, 77–79. 
75.  Gatchel, J.R.; Zoghbi, H.Y. Diseases of unstable repeat expansion: Mechanisms and common 
principles. Nat. Rev. Genet. 2005, 6, 743–755. 
76.  Cha,  J.H.  Transcriptional  dysregulation  in  huntington’s  disease.  Trends  Neurosci.  2000,  
23, 387–392. 
77.  Kemp,  M.Q.;  Poort,  J.L.;  Baqri,  R.M.;  Lieberman,  A.P.;  Breedlove,  S.M.;  Miller,  K.E.;  
Jordan, C.L. Impaired motoneuronal retrograde transport in two models of SBMA implicates two 
sites of androgen action. Hum. Mol. Genet. 2011, 22, 4475–4490. 
78.  Malik,  B.;  Nirmalananthan,  N.;  Bilsland,  L.G.;  La  Spada,  A.R.;  Hanna,  M.G.;  Schiavo,  G.;  
Gallo, J.M.; Greensmith, L. Absence of disturbed axonal transport in spinal and bulbar muscular 
atrophy. Hum. Mol. Genet. 2011, 20, 1776–1786. 
79.  Lorson,  C.L.;  Rindt,  H.;  Shababi,  M.  Spinal  muscular  atrophy:  mechanisms  and  therapeutic 
strategies. Hum. Mol. Genet. 2010, 19, R111–R118. 
80.  Kong, L.; Wang, X.; Choe, D.W.; Polley, M.; Burnett, B.G.; Bosch-Marcé, M.; Griffin, J.W.; 
Rich, M.M.; Sumner, C.J. Impaired synaptic release and immaturity of neuromuscular junctions in 
spinal muscular atrophy mice. J. Neurosci. 2009, 29, 842–851. 
81.  Dale, J.M.; Shen, H.; Barry, D.M.; Garcia, V.B.; Rose, F.F., Jr.; Lorsen, C.L.; Garcia M.L. The 
spinal muscular atrophy mouse model, SMA 7, displays altered axonal transport without global 
neurofilament alterations. Acta Neuropathol. 2011, 122, 331–341. 
82.  Blackstone, C.; O’Kane, C.J.; Reid, E. Hereditary spastic paraplegias: membrane traffic and the 
motor pathway. Nat. Rev. Neurosci. 2011, 12, 31–42. 
©  2012  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 